# HCPLive

> HCPLive - Healthcare Publication

- Base URL: https://www.hcplive.com
- Generated: 2026-09-16T04:32:48.812Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.hcplive.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.hcplive.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.hcplive.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.hcplive.com/robots.txt](https://www.hcplive.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [10 Year Plan Series](https://www.hcplive.com/10-year-plan-series)
- [Advanced Practitioners Corner](https://www.hcplive.com/advanced-practitioners-corner)
- [Clinical](https://www.hcplive.com/clinical)
- [Clinical Trial Insights](https://www.hcplive.com/clinical-trial-insights)
- [Conference](https://www.hcplive.com/conference)
- [Explore the Endogenous Opioid System And its Potential Impact on MDD](https://www.hcplive.com/alkermes)
- [Insights](https://www.hcplive.com/insights)
- [Insights](https://www.hcplive.com/insights)
- [Journals](https://www.hcplive.com/journals)
- [Medcast Videos](https://www.hcplive.com/medcast-videos)
- [NO ADS](https://www.hcplive.com/noads)
- [News](https://www.hcplive.com/news)
- [Peer Exchange](https://www.hcplive.com/peer-exchange)
- [Peers Perspectives](https://www.hcplive.com/peers-perspectives)
- [Physician's Money Digest](https://www.hcplive.com/physicians-money-digest)
- [Plastic surgery](https://www.hcplive.com/plastic-surgery)
- [Podcasts](https://www.hcplive.com/podcasts)
- [Post Conference Perspectives](https://www.hcplive.com/post-conference-perspectives)
- [Practice Brief](https://www.hcplive.com/practice-brief)
- [Press Release](https://www.hcplive.com/press-release)
- [Publications](https://www.hcplive.com/journals)
- [Q1 Awareness Highlights](https://www.hcplive.com/q1-awareness-highlights)
- [Qazi Corner](https://www.hcplive.com/qazi-corner)
- [Quizzes](https://www.hcplive.com/quizzes)
- [Rosacea](https://www.hcplive.com/rosacea)
- [Shows](https://www.hcplive.com/shows)
- [Special Reports](https://www.hcplive.com/news-network)
- [Sponsored](https://www.hcplive.com/sponsored)
- [Strategic Alliance Partnership](https://www.hcplive.com/sap-partner)
- [The Respiratory Report](https://www.hcplive.com/respiratory-report)
- [This Year In Medicine](https://www.hcplive.com/this-year-in-medicine)
- [Venous Thromboembolism](https://www.hcplive.com/vte)
- [Video Series](https://www.hcplive.com/video-series)
- [Videos](https://www.hcplive.com/videos)

## Featured Content

- [Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD](https://www.hcplive.com/view/dupilumab-cuts-copd-exacerbations-across-seasons-smoking-status-bhatt): Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.
- [Where is Precision Medicine Today in Dermatology?](https://www.hcplive.com/view/where-is-precision-medicine-today-dermatology-): In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
- [Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD](https://www.hcplive.com/view/vicadrostat-easi-kidney-trial-discontinued-for-lack-of-benefit-in-ckd): Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.
- [FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD](https://www.hcplive.com/view/fibroneer-on-nerandomilast-durable-ipf-ppf-safety-wuyts): Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
- [Catheter Ablation Improves, May Reverse HFpEF Symptoms in Patients With AF](https://www.hcplive.com/view/catheter-ablation-improves-may-reverse-hfpef-symptoms-in-patients-with-af): Jonathan Piccini, MD, discusses his presentation at ESC 2026 discussing the potential benefits of catheter ablation in concomitant HFpEF and AF.
- [FAQ: What the New BEACON-HCC Framework Changes in HCC Treatment](https://www.hcplive.com/view/faq-how-beacon-hcc-actually-differs-from-bclc-in-practice): BEACON-HCC offers a new approach to HCC treatment allocation, with key differences from the updated BCLC framework.
- [Wildfire Smoke and Delayed Allergic Sensitization, with Jim Blando, PhD](https://www.hcplive.com/view/wildfire-smoke-delayed-allergic-sensitization-blando): Jim Blando, PhD, of Old Dominion University, explains why allergic patients' lung function dropped most 1 year after wildfire smoke exposure.
- [Inside FIND-CKD: The Data Behind the Trial's 23% Risk Reduction](https://www.hcplive.com/view/inside-find-ckd-the-data-behind-trial-23-risk-reduction): Brendan Neuen breaks down the full FIND-CKD primary and secondary endpoint data, subgroup consistency, and safety signals.
- [Diabetes Dialogue: Beta Bionics' Mint Patch Pump Gains FDA Clearance](https://www.hcplive.com/view/diabetes-dialogue-beta-bionics-mint-patch-pump-gains-fda-clearance): Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
- [Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data](https://www.hcplive.com/view/atacicept-cuts-igan-progression-risk-76-in-origin-3-final-data): Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.

## Feeds and Indexes

- [RSS Feed](https://www.hcplive.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.hcplive.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.hcplive.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.hcplive.com/authors): Browse all contributors and their published work